Biological NTLA-2002
Phase 2Biologic
Intellia TherapeuticsBiological NTLA-2002 is one of 13 biologic programs targeting Hereditary Angioedema. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Hereditary Angioedema
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Crestor
AstraZenecaApproved
Lanoxin
AAdvanz Pharma
Approved
Andembry
CSL BehringApproved
Dawnzera (autoinjector)
Ionis PharmaceuticalsPhase 3
Orladeyo
BBioCryst Pharmaceuticals
Phase 3
Deucrictibant
PPharvaris Netherlands B.V.
Phase 3
KVD900
KKalVista Pharmaceuticals, Ltd.
Phase 3
ADX-324
AADARx Pharmaceuticals, Inc.
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biological NTLA-2002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company